Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ Exercises Merck non-PPI Buyout | Contract Pharma

What are you searching for?

Sign in
Breaking News

AZ Exercises Merck non-PPI Buyout

AstraZeneca will exercise its option to buy out Merck's interest in AZ's non-PPI products for $647 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca will exercise its option to buy out Merck’s interest in AZ’s non-proton pump inhibitor (non-PPI) products this year for $647 million. The products are Atacand, Lexxel, Plendil and Entocort, as well as several products in development. The option price reflects Merck’s share of projected pretax revenue for the products.

The buy-out triggers AZ’s option to acquire Merck’s interest in AZ’s PPI products, including Nexium, in 2012 or later.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters